These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106. Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib. Fujioka S; Kitajima T; Itotani R J Thorac Oncol; 2018 Aug; 13(8):e137-e139. PubMed ID: 30049374 [No Abstract] [Full Text] [Related]
107. Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis: A case report. Liu N; Zheng L; Yu M; Zhang S Medicine (Baltimore); 2021 Feb; 100(8):e24569. PubMed ID: 33663064 [TBL] [Abstract][Full Text] [Related]
109. Segmentectomy of the left superior segment (S Shimizu K; Nakazawa S; Mogi A; Kuwano H J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1302-1304. PubMed ID: 28986040 [No Abstract] [Full Text] [Related]
110. Vortex Keratopathy Presumed Secondary to AZD9291. Chia PL; John T J Thorac Oncol; 2015 Dec; 10(12):1807-8. PubMed ID: 26709481 [No Abstract] [Full Text] [Related]
111. Mesenchymal-epithelial Transition Exon 14-skipping Mutation-positive Invasive Mucinous Adenocarcinoma of the Lung: First Case Treated with Mesenchymal-epithelial Transition-tyrosine Kinase Inhibitors. Okuzumi S; Suzuki H; Morinaga S; Tamura M; Minematsu N Intern Med; 2024 Jun; 63(12):1789-1795. PubMed ID: 37952955 [TBL] [Abstract][Full Text] [Related]
112. High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy. Kotake M; Murakami H; Kenmotsu H; Naito T; Takahashi T Ann Oncol; 2017 Mar; 28(3):669-670. PubMed ID: 27993813 [No Abstract] [Full Text] [Related]
113. Cutaneous adverse events following treatment with third-generation EGFR tyrosine kinase inhibitors. Li Pomi F; Vaccaro F; Borgia F; Irrera N; Vaccaro M Ital J Dermatol Venerol; 2024 Apr; 159(2):212-214. PubMed ID: 38261309 [No Abstract] [Full Text] [Related]
114. Osimertinib-related venous thromboembolism in non small lung cancer. Petrelli F; Cabiddu M; Borgonovo K; Parati MC; Ghilardi M; Perego G; Luciani A Thromb Res; 2022 Feb; 210():63-66. PubMed ID: 35007938 [No Abstract] [Full Text] [Related]
115. Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review. Hong G Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138247 [TBL] [Abstract][Full Text] [Related]
116. Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib. Frankel D; Kaspi E; Liprandi A; Dales JP; Roll P Cytopathology; 2022 Sep; 33(5):633-635. PubMed ID: 35689552 [TBL] [Abstract][Full Text] [Related]
117. Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial. Arrieta O; Zatarain-Barrón ZL; Turcott JG; Barrón F; Yendamuri S; Cardona AF; Rosell R JAMA Oncol; 2022 Mar; 8(3):477-479. PubMed ID: 35024769 [TBL] [Abstract][Full Text] [Related]
118. EGFR-TKI plus antiangiogenic agent combination therapy may reduce the incidence of EGFR-TKI-associated interstitial lung disease in Asian. Lee TH; Chen HL; Tsai MJ; Yang CJ Kaohsiung J Med Sci; 2022 Nov; 38(11):1133-1134. PubMed ID: 36053872 [No Abstract] [Full Text] [Related]
119. Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC. Klempner SJ; Hata AN J Thorac Oncol; 2019 Nov; 14(11):1875-1877. PubMed ID: 31668312 [No Abstract] [Full Text] [Related]
120. Welcome to the Real World: Understanding the Many Faces of Osimertinib-Related Pneumonitis. Possick JD Chest; 2022 Nov; 162(5):965-967. PubMed ID: 36344125 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]